Tag Archives: featured

The Death of Death

Heales Monthly Letter. The Death of Death. N°157. April 2022. Self-experimentation and longevity

« I am also happy that we can let science progress, that we can give it the means to progress. Because even if there are risks, the progress of science, we owe it a lot for the quality of our life and especially the extension of our life expectancy. And as long as we are not quite sure of what comes afterwards, we must hope that science will continue to keep us alive and in good health as long as possible here on earth ».


Pierre-Yves Maillard, Vice President of the Swiss Socialist Party, 2013.

Theme of the month: Self-experimentation and longevity

Introduction

The slow progress of medical therapies for a much longer healthy life has multiple causes: cumbersome, time-consuming and costly regulations, patents preventing knowledge sharing, lack of transparency due to privacy laws, lack of publication of results and experimentation on the elderly, and lack of trials that rigorously respect scientific principles including double-blinding. This letter examines some of the ways in which this research can be accelerated.

Definition

Self-experimentation refers to the special case of research in which the researcher performs the experiment on himself.

Also known as personal scientific research, self-experimentation is an example of participatory science since it can also be conducted by patients or people interested in their own health and well-being, as both research subjects and self-experimenters.

It should be noted that in addition to self-experimentation, in order to obtain faster results, some people carry out what is called a « Human challenge study » or « Challenge trials », i.e. experiments involving the intentional exposure of the subject to the condition being tested (e.g. voluntary exposure to viral diseases for vaccine trials).

History

Self-experimentation has been practiced for centuries. Many scientists have risked their own health to help advance medicine.

Among the pioneers of self-experimentation:

More recently, best-selling author Tim Ferriss claims to be an extreme self-experimenter. Alexander Shulgin, an American pharmacologist and chemist. He is known for creating new psychoactive chemicals. He has devoted his entire career to self-experimentation, publishing his results in widely acclaimed books. Finally, Josiah Zayner (The Odin company) is a famous biohacker who in 2016 performed a microbiome transplant including a fecal transplant, in an attempt to solve health problems (notably gastrointestinal).

The « Quantified Self » is a phenomenon born in the USA in the 2000s, which consists of using connected tools or mobile applications dedicated to health in order to measure, analyze and share personal data. Among the connected tools, there are physical activity monitors (bracelets, watches, pedometers…), sleep recorders, connected scales or mobile applications dedicated to women’s health (menstruation monitoring, pregnancy…).

Self-experimentation in the field of longevity

Liz Parrish, CEO of BioViva, is one of the most well-known self-testers. In 2015, she traveled to Colombia to become « patient zero » (= the 1st person to test) of two anti-aging therapies. These consist of two types of injections: a myostatin inhibitor to prevent age-related muscle loss; and a telomerase gene therapy to lengthen telomeres.

Some people, mostly self-taught and called biohackers, also engage in research for longevity by experimenting on themselves.

This is the case for Ken Scott, a 78-year-old longevity enthusiast who has changed his lifestyle over the past 10 years. Every three months, he injects 1 cc of amniotic exosomes and Dasatinib, an anti-cancer drug that is believed to help kill harmful senescent cells in the body.

For these experimenters, the FDA rules governing clinical trials frustrate their desire to try new medical technologies. In addition, there is also the issue of cost and time. A study conducted by the London School of Economics found that the average price to bring a drug to market was $1.3 billion. And research by BIO, found that it takes an average of 10.5 years from the time a drug is in Phase 1 of a clinical trial, i.e., the first human trial, to the time of regulatory approval.

Fortunately for biohackers, there are many cheaper and easier to access tools to measure their own medical data. For example, InsideTracker, a health monitoring company in the US, offers a complete analysis for $590 including a test on 43 blood biomarkers.

In addition, one of the most knowledgeable longevitists, named Reason, has published detailed how-to guides for self-experimentation on his Fight Aging website.

Conclusion

Self-experiments allow medical advances. With regard to aging, this is particularly desirable because most « classic » trials are done on young or very healthy subjects. What should be studied is the effect on elderly people or people in declining health.

It is important that legislative changes allow or even favor such research without delay and without any requirement other than the guarantee of truly free (i.e. financially disinterested) and informed consent.

The good news of the month but also the bad news of the global toll of the Covid-19 epidemic.

Jean-Marc Lemaître‘s new book « Guérir la vieillesse » is out. « What if old age was a disease and we could cure it? » 

A study recently published in PLOS Medicine shows that healthy life expectancy is increasing (= the number of healthy years a person lives) even for people with common chronic diseases. Holly Bennett and the other researchers wanted to determine whether this extension of life involves an increase in years with or without disability. The team analyzed data from two large population-based studies of people aged 65 or older in England. For men and women with cognitive impairment, there is an increase in the percentage of years remaining on disability for both men and women. But overall, the average number of years of disability-free life expectancy increased between 1991 and 2011. For example, women gained 2.0 years and men gained 3.7 years. 

But alongside this good news, there is unfortunately some bad news. An assessment of the impact of Covid-19 on life expectancy has been made by the American researcher P. Heuveline. This assessment is catastrophic. It is the first decrease in life expectancy in the world since 1950. This was not only the case for one year, but for two consecutive years. Global life expectancy decreased by 0.92 years between 2019 and 2020 and by another 0.72 years between 2020 and 2021. The world’s citizens have returned to the life expectancy of 10 years ago. These annual declines in life expectancy mean more than 15 million additional deaths in 2020 and 2021. Please note that this figure is still provisional. It is to be refined, but above all, there is no certainty of a return to normal. Especially if attention slackens, if the support to medical research weakens… For the longevitists of 2022, it will no longer be enough to « channel the river of progress », it will be necessary to reverse the current trend in terms of real impact on health. 

Other scientific news in April from Heales.

For more information

The Death of Death

Heales Monthly Letter. The Death of Death. N°156. March 2022. Breathing and Longevity

The longevity revolution (…) that is taking place today and (…) will change human life, probably more than any other revolution we have known in human history. (…) A number of very serious scientists are telling us about this longevity revolution.

They are not crazy American billionaires, nor delusional transhumanists. They are, for example, Jean-Claude Ameisen, who was the president of the ethics committee, who is a very serious guy. (…) I have a whole series of quotes from extraordinarily serious medical professors who say that we are in the process of experiencing this revolution of longevity.

Luc Ferry. December 2021. Meeting of the future (translation).

Theme of the month: Breathing and longevity

Introduction

In the early history of life, for over a billion years, oxygen was a violent poison for the first organisms. This was in the days of single-celled organisms, when organisms were unlikely to age.

Today, oxygen is necessary for the majority of living species. Lungs appeared in marine species at least 420 million years ago. In humans, lungs are the almost exclusive source of respiration.

In the course of a lifetime, we inhale about 300 million liters of air. One liter of air weighs just over one gram, so the 12 cubic meters we take in and breathe out each day is approximately 15 kilos of gas.

When inhaled, the air is composed mainly of nitrogen (78%) and oxygen (21%). Carbon dioxide (CO2 ) accounts for only 0.04% of the air inhaled. Oxygen is needed for the body’s metabolism, and carbon dioxide must be removed.

The exhaled air is depleted of oxygen (17%) and enriched with water vapor and CO2   (4%). On exhaling, the air is also loaded with invisible aerosols. These contain viruses and bacteria, possibly pathogenic, from the respiratory tract and the oral cavity. These aerosols contribute to the phenomenon of contagion, even in the absence of coughing and sneezing. The rate of respiratory aerosol tends to increase with age.

Unfortunately, we also absorb these organisms from our relatives as well as many other substances, such as fine particles from pollution, allergens, etc.

Breathing also allows us to use our sense of smell, the fascinating capacity of olfactory cells that allow our brain to distinguish between millions of odors based on minute quantities of volatile substances. With advancing age, these abilities, like others, imperceptibly but, until today, irreversibly diminish.

What are the main lung diseases? Three main categories

  • Acute illnesses : 

Infectious diseases of the bronchial tubes (bronchitis) or lung tissue (pneumonia). In both cases, the disease is bacterial or viral in origin. Pneumonia can also be caused by a fungus and bronchitis by irritants such as smoke.

The elderly are very vulnerable to these diseases. Aging favors the entry of infections because defenses are weaker and because there are usually other pathologies or chronic diseases present.

Bronchitis is rarely fatal but can become chronic. Pneumonia, on the other hand, can have serious consequences for an elderly person and lead to death. Nearly one in five centenarians dies from pneumonia, compared to only 6% of 80-85 year olds.

  • Chronic lung diseases including :

Asthma can develop at any age. When an older person develops asthma, the symptoms are mostly the same as those affecting younger people. However, it is more risky for an older person because they are more likely to develop other respiratory problems.

COPD (Chronic Obstructive Pulmonary Disease) is a common inflammatory disease of the bronchial tubes. It is often the result of heavy exposure to inhaled toxic substances such as tobacco or pollution. In the elderly, it often develops into a respiratory disability requiring oxygen at home.

  • Lung cancer :

Lung cancer is primarily caused by smoking, but also by exposure to substances such as asbestos or fine particle pollution. In Belgium, it is the 3rd most common cancer. Every year, more than 3000 people between 60 and 70 years old get lung cancer. The frequency of these cancers increases with age, but decreases after 70 years. It is one of the most dreaded cancers as only 18% of men and 16% of women survive more than 5 years.

Why are respiratory diseases more common in older people?

Because aging involves: 

  • Decreased muscle strength, especially in the intercostal muscles, back muscles and respiratory muscles.
  • Decreased cough strength.
  • Decreased airway clearance.
  • Decreased tissue elasticity due to degeneration of elastic fibers and changes in collagen.
  • Inflamm-age » phenomenon.
  • Changes in the immune response.
  • …

Medical advances and research

  • Antioxidants

We can first note that, especially in the past, antioxidants have been considered as a means to fight aging. The idea is that respiration generates free radicals with deleterious effects and that substances can absorb these radicals. However, this concerns respiration at the level of the cell, not specifically the lungs. Furthermore, to date, no antioxidant has demonstrated a significant and undisputed longevity effect. 

  • Gene therapy for lung disease

As far as respiratory diseases are concerned, many are chronic and often of genetic origin.

The lungs are an accessible organ for gene therapy, but the complexity of the lung structure presents certain physical and chemical barriers to the delivery of viral vectors. In addition to these barriers, symptoms such as a thick mucus layer in the case of cystic fibrosis complicate the process.

A study published in the Journal of Clinical Medicine in 2020 summarizes the various advances in gene therapy for respiratory diseases such as cystic fibrosis, alpha-1 antitrypsin deficiency (AATD) and primary ciliary dyskinesia (PCD).

In recent decades, there have been great advances in gene therapies for respiratory diseases. However, researchers are still working on new breakthroughs due to ongoing concerns about safety, specificity and efficacy.

  • Stem cells

As in most of the rest of the body, stem cells are found in the lungs. The use of stem cells for regeneration is being researched. In particular, the creation of organoids is possible, but there are no real direct applications for older humans.

  • Transplants

Lung and trachea transplants are still exceptional operations. As for other organs, xenotransplantation (organ from animals) and bioprinting (printing of tissues or organs) are also envisaged, but not yet carried out.

And further on

Here, as elsewhere, the combination of growing knowledge, coupled with broad-based commitment and funding, can lead to incremental progress and breakthroughs. For example, the catastrophic effects of covid on the respiratory system of the elderly have been rapidly reduced. This is one of the reasons for the insufficient but significant decrease in mortality from this disease.

Good news of the month:
Effective cellular reprogramming in aged mice

It was already well known that the addition of a mixture of 4 reprogramming molecules under the name « Yamanaka factors » to cells can reset epigenetic marks to their original state. This partial reprogramming over short periods of time counteracts the signs of aging and increases the lifespan of mice with premature aging disease.

In March 2022, in a paper published in Nature Aging: « In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. « In this paper, it is found that long-term partial reprogramming leads to rejuvenation effects in different mouse tissues. And that the duration of the treatment determines the extent of the beneficial effects.

In a recent study conducted by Prof. Juan Izpisua Belmonte and his teams at the Gene Expression Laboratory of the Salk Institute for Biological Studies, researchers performed various long-term partial reprogramming regimes in healthy animals, including at different onset times, during physiological aging.

A first group of mice received regular doses of Yamanaka factors from 15 months to 22 months of age (human equivalent: +/- 50 to 70 years). A second group was treated from 12 to 22 months (human equivalent: +/- 35 to 70 years). And finally, a third group was treated for only one month at the age of 25 months (human equivalent: +/- 80 years). Unfortunately, for these experiments as for many others on rats or mice, as the animals are sacrificed at the end of the experiment to be able to analyze their physiological state, the real result in terms of maximum lifespan is not known.

Compared to control animals, there were no alterations in blood cells or neurological changes in mice that received Yamanaka factors.

The researchers claim that the rejuvenating effects are associated with a reversal of the epigenetic clock and metabolic and transcriptomic changes. The scientific team is now planning future research to analyze how specific molecules and genes are modified by long-term treatment with Yamanaka factors.

For more information: